News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY)'s Perjeta on US Fast-Track for Early Breast Cancer


7/2/2013 6:32:13 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Roche's Perjeta is one of the first drugs to take advantage of a new regulatory pathway in the US that is designed to get new drugs for early-stage breast cancer to market quicker.

Perjeta (pertuzumab) has been granted priority review by the FDA for use before surgery (neoadjuvant treatment) in women with HER2-positive breast cancer, setting it up for approval in the new indication by the end of October 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release

comments powered by Disqus
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES